Chemical formula: C₈H₁₁NO₃ Molecular mass: 169.178 g/mol PubChem compound: 439260
Noradrenaline interacts in the following cases:
By extrapolation from non-selective MAO inhibitors, risk of increase in the pressor action. Should only be used under close medical supervision.
Increase in the pressor action of the sympathomimetic which is usually moderate. Should only be used under close medical supervision.
Severe ventricular arrhythmia (increase in cardiac excitability).
Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of sympathomimetics into sympathetic fibres).
In general, cautious evaluation is recommended in the following case of hypotension and hypoperfusion, in which a reduction in the dose of noradrenaline may be required.
Major left ventricular dysfunction associated with acute hypotension: supportive therapy should be initiated simultaneously with diagnostic evaluation. Noradrenaline should be reserved for patients with cardiogenic shock and refractory hypotension, in particular those without elevated systemic vascular resistance.
Caution is advised in patients with hyperthyroidism or diabetes mellitus.
In general, cautious evaluation is recommended in the following case of hypotension and hypoperfusion, in which a reduction in the dose of noradrenaline may be required.
Hypotensive patients diagnosed with coronary, mesenteric or peripheral vascular thrombosis, myocardial infarction or Prinzmetal’s variant angina: particular caution should be observed as noradrenaline may increase the associated ischaemia and extend the area of infarction.
Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of sympathomimetics into sympathetic fibres).
Because of its indications, noradrenaline may be administered if necessary during pregnancy. However, pharmacodynamics properties of the substance have to be considered. Noradrenaline may impair placental perfusion and induce fetal bradycardia. It may also exert a contractile effect on the pregnant uterus and lead to fetal asphyxia in late pregnancy.
No information is available on the use of noradrenaline in lactation.
Not relevant.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
